Key facts
- It has raised $29.2M; the latest was Later Stage VC ($13.8M) in Mar 2025.
- Notable investors include HSG (Hong Kong), GF Xinde Investment Management, China Growth Capital, Co-Win Ventures, Sichuan Venture Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Geneus (China)
- ·The full record, as it builds
Funding rounds
No funding rounds for Geneus (China) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Geneus (China)
Developer of gene sequencing technology designed to promote the development of precision medicine. The company's business scope covers software and hardware for sequencers, sample processing, consumables, reagents and data processing, enabling genetic sequencing to be a routine detection and diagnostic tool for medical industry.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2017
- Employees
- 80
- Website
- geneus-tech.com/
- Ownership
- Privately Held (backing)
Geneus (China) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Geneus (China) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Geneus (China) in its N-PORT filings yet. We sweep new filings monthly.